Soligenix

315 articles with Soligenix

• Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform

  2/27/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that its ongoing collaboration with the University of Hawai'i at Manoa (UHM) and Hawaii Biotech Inc (HBI) has resulted in what the Company believes is a significant milestone in the development of heat stable filovirus vaccines,

• FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning

  2/13/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its RiVax

• Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas

  2/11/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma

• Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis

  2/3/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japanese Patent Office has granted the patent titled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis." 

• Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference

  1/30/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 22nd Annual BIO CEO & Investor Conference in New York Cit

• Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  12/18/2019

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.

• Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine

  12/12/2019

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened the study titled "A Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety of RiVax

• Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

  12/3/2019

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL)

• Soligenix to Present at the PCG Spotlight Series Conference

  11/18/2019

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the PCG Spotlight Series Conference taking place on Thursday, November 21, 2019 at the Harvard Club, 35 West 44th Street, NYC at 2:30 pm EST.

• Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

  11/12/2019

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended September 30, 2019.

• Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

  11/6/2019

  Soligenix, Inc. announced that Daniel P. Ring, Vice President of Business Development and Strategic Planning, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, Tuesday, November 12, 2019 at 10:45 AM GMT.

• Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition

  10/24/2019

  Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

• Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

  10/3/2019

  Review of Two Phase 3 Clinical Programs with Near-Term Readouts

• Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning

  9/16/2019

  Industry veteran brings extensive experience leading business development

• Soligenix Appoints Jonathan Guarino as Chief Financial Officer

  9/11/2019

  Seasoned executive with over two decades of financial and commercial business experience

• Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

  8/29/2019

  Review of Upcoming Milestones for Two Phase 3 Clinical Programs

• Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

  8/28/2019

  Final topline results remain on target for first half 2020

• Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

  8/15/2019

  Soligenix, Inc. announced that the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, has awarded Soligenix a Phase I Small Business Innovation Research of approximately $150,000 to support the evaluation of SGX942 in pediatric indications.

• Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results

  8/13/2019

  Announced today its recent accomplishments and financial results for the quarter ended June 30, 2019.

• 2019 Colorado Protein Stability Conference Posters Now Available

  8/4/2019

  The two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference are now available.